HemoBioTech Announces Dramatic Clearance Of Prions With The ORTH Technology

Main Category: CJD / vCJD / Mad Cow Disease
Article Date: 12 Mar 2009 - 1:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

HemoBioTech (OTCBB:HMBT) announced that their orthogonal (ORTH) technology showed to be extremely effective in elimination of prion proteins that cause mad cow disease (BSE) and a similar disease in humans (vCJD/CJD). The ORTH technology removed prion proteins at a rate of 10 -10 from biological fluids used to make specific pharmaceutical products.

This clearance is about 100,000 times greater than is required by the FDA and has the potential for establishing a new standard for pharmaceutical products made from bovine (cow) or human plasma sources. The GLP validation of the ORTH technology was performed by BioReliance Laboratories in Rockville, MD and Glasgow, Scotland, using FDA accepted techniques.

Multiple medical and cosmetic products are made from bovine sources such as serum and collagen, as well as from human plasma, such as albumin, immunoglobulins, thrombin, fibrinogen and other clotting factors. The market for such products is approximately $7 billion. One important regulatory requirement for these products is the effective clearance of prion proteins. The ORTH technology has the potential to play a significant role in the production of some of these products.

HemoBioTech is using the ORTH technology for purification of their bovine hemoglobin that is chemically modified with ATP, Adenosine and GSH to make its lead product HemoTech, which potentially is the first viable substitute for human blood. Based on data to date, the Adenosine and GSH overcome hemoglobin intrinsic toxicity, which has plagued all other attempts to develop a substitute for human red blood cells. HemoTech is being developed for uses in trauma, surgery and ischemia. About 10% of new HIV AIDS cases globally are caused by HIV contaminated blood, HemoTech has the potential to be an alternative to contaminated blood.

The proprietary ORTH technology involves several biotechnological steps, such as nanofiltration, chromatography and chemical treatment, during the purification of the products resulting in orthogonal clearance and inactivation of prions. The ORTH technology was developed at Texas Tech University by Dr. Jan Simoni and his colleagues and HemoBioTech has an exclusive worldwide license to commercialize ORTH. HemoBioTech is pursuing sublicensing the ORTH technology to pharmaceutical and biotechnology companies in return for upfront fees, milestone payments and royalties. Interested parties should contact Dr. Arthur P. Bollon, Ph.D., Chairman and CEO of HemoBioTech, at arthurb@flash.net or 972-455-8955

"We are very excited about the efficiency of the prion clearance using the ORTH technology. Bovine and human plasma medical products represent a significant medical market and we offer the ORTH technology to the biotechnology and pharmaceutical industry for production of these important products," said Dr. Arthur P. Bollon, Ph.D., Chairman and CEO of HemoBioTech.

About HemoBioTech, Inc

HemoBioTech is engaged in the commercial development of HemoTech, a novel human blood substitute technology developed by Texas Tech University Health Sciences Center scientists, Drs. Mario Feola and Jan Simoni, and exclusively licensed from Texas Tech University System. HemoTech is composed of bovine hemoglobin that is chemically modified with ATP, Adenosine and GSH. HemoTech not only can carry oxygen in the blood, but can also induce erythropoiesis (red blood cell production). The Company believes that HemoTech, due to its novel structure, may possess properties that diminish the intrinsic toxicities that have plagued other attempts at developing blood substitutes, based upon pre-clinical and initial human clinical trials undertaken outside the U.S. HemoTech is being subjected to further studies and testing to confirm and expand on these studies.

At a recent meeting in April 28-29, 2008 by the U.S. Food and Drug Administration (FDA) for blood substitutes, the FDA indicated the need for a new generation of hemoglobin based blood substitutes and the Adenosine-GSH approach of HemoTech was cited. HemoTech is being developed to help reduce or eliminate the danger resulting from acute blood loss in trauma, as well as for other conditions. The Company is also pursuing the sublicense of ORTH technology for the clearance of prions and viruses during the purification of medical and cosmetic products derived from bovine and human plasma sources. The ORTH technology was developed Dr. Simoni at Texas Tech University and HemoBioTech has an exclusive worldwide license. Corporate headquarters are located at 5001 Spring Valley Road, Suite 1040-West, Dallas, Texas 75244. For further information contact, Dr. Arthur Bollon at 972-455-8955, arthurb@flash.net or visit our website at: http://www.hemobiotech.com.

Safe Harbor Statement

Except for historical information, the matters discussed in this news release may be considered "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of HemoBioTech and its management and are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others the successful pre-clinical development, the successful completion of clinical trials, the FDA review process and other governmental regulation, pharmaceutical collaborator interest and ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement, and other factors which are included in HemoBioTech's Annual Report on Form 10-K for the year ending December 31, 2007, as amended, and HemoBioTech's other reports filed with the Securities and Exchange Commission.

HemoBioTech, Inc